PolyU RCMI, MCMIA and GP-TCM RA co-organise Forum on Global Regulatory Challenges in Herbal Drug Innovation
[Hong Kong, 10 November 2026] The PolyU Research Centre for Chinese Medicine Innovation (RCMI), the Modernized Chinese Medicine International Association (MCMIA) and the Good Practice in Traditional Chinese Medicine Research Association (GP-TCM RA) successfully co-hosted the University-Industry Collaboration Forum: Navigating Global Regulations to Accelerate Herbal Drug Innovation at The Hong Kong Polytechnic University (PolyU). The Forum brought together leading academics, industry experts, and regulatory officials to explore strategies for overcoming regulatory barriers and advancing innovation in the global herbal medicine sector. Nearly 100 participants attended in person or online, underscoring the significance and timeliness of the theme.
Distinguished speakers including Prof. Dennis CHANG, Director and Professor of Pharmacology of the NICM Health Research Institute, Western Sydney University, Australia; Prof. Rudolf BAUER, Professor Emeritus of the University of Graz, Austria; Dr. MA Yuan-Chun, CEO and Chairman of the Dr. Ma’s Laboratories Inc., Canada; and Prof. LIU Jianping, Director of the Center for Evidence-Based Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, China. They shared the latest developments in herbal pharmacology, standardisation, and regulatory compliance, shedding light on ways to align scientific research with international safety and efficacy standards.
A highlight of the event was the panel discussion featuring prominent leaders from both the clinical and commercial sectors:
Prof. Bernard M. Y. CHEUNG, Chief Executive Officer of the Greater Bay Area International Clinical Trial Institute, HKSAR, China;
Prof. Paul LI, Professor, Department of Chemistry of the Simon Fraser University, Canada; and
Mr. Abraham CHAN, Founder, Chairman and CEO of the PuraPharm Corporation Limited, HKSAR, China.
The panellists engaged in a dynamic discussion on the pathways for translating laboratory research into market-ready products, highlighting the importance of the Greater Bay Area as a hub for clinical trials and the role of international partnerships in meeting global regulatory requirements.
Speaking at the Forum, Dr Vincent CHUNG Chi-ho, Commissioner for Chinese Medicine Development of the HKSAR Government, emphasised the need for cross-sector collaboration to accelerate the translation of research into real-world healthcare solutions. He said: “This Forum underscores our commitment to bridging the gap between academic research and industrial application. By navigating global regulations together, we can ensure that high-quality herbal innovations reach patients safely and efficiently.”
The Forum marked an important step towards strengthening collaboration across the herbal medicine ecosystem. Looking ahead, RCMI will continue to foster dialogue, partnerships and knowledge exchange to advance integrative medicine and natural product research.
【香港,2026年11月9日】香港理工大學(理大)中醫藥創新研究中心、現代中醫藥國際協會及中醫藥規範研究學會於理大合辦「產學研合作論壇:對接國際法規標準,加速草本藥物創新」。論壇匯聚學術界、業界及監管機構代表,共同探討應對法規挑戰的策略,推動全球草本藥物領域的創新發展。近 100 名參加者透過現場或線上方式參與,反映議題備受關注,切合業界當前需要。
論壇邀得多位國際知名專家擔任講者,包括澳洲西悉尼大學藥理學教授兼國家輔助醫學研究院院長張旭東教授、奧地利格拉茨大學榮休教授鲍儒德教授、加拿大馬氏實驗室行政總裁兼主席馬元春博士,以及成都中醫藥大學附屬醫院循證醫學中心主任劉建平教授。各講者分享草本藥理學、標準化及法規合規方面的最新進展,探討如何使科研成果符合國際安全及療效標準。
論壇的一大亮點為專題討論環節,邀得臨床及商界領袖参與:
粵港澳大灣區國際臨床試驗所行政總裁張文勇教授
加拿大西門菲莎大學化學系教授李保華教授
香港培力控股有限公司創辦人、主席兼行政總裁陳宇齡先生
嘉賓深入探討將實驗室研究成果轉化為市場產品的路徑,並強調粵港澳大灣區作為臨床試驗樞紐的重要地位,以及國際合作在符合全球監管要求方面的關鍵作用。
香港特別行政區政府中醫藥發展專員鍾志豪博士於論壇上致辭時,強調跨界別合作對加快科研成果轉化為實際醫療方案的重要性。他表示:「此次論壇彰顯了我們致力促進學術研究與產業應用對接的決心。透過共同應對全球法規要求,我們能夠確保優質的草本藥物創新成果以安全及高效的方式惠及患者。」
是次論壇為加強草本藥物領域的協作邁出重要一步。展望未來,理大中醫藥創新研究中心將繼續促進跨界別交流、夥伴合作及知識共享,推動整合醫學與天然產物研究的發展。